ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients

Now, after a successful phase 3 trial, Opsynvi may be on its way to winning more regulatory green lights.

On Monday, results from a pivotal study called A DUE showed that Opsynvi—which consists of 10 mg of Opsumit and 40 mg of Adcirca—significantly improved blood flow through pulmonary blood vessels versus either drug as a monotherapy. The results were presented at the American College of Cardiology’s 72nd Annual Scientific Session in New Orleans.